Sankala Group’s Moderna MRNA Stock Holding History

Sankala Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$644K	Buy	10,105 +1,787	+21%	+$92.5K	0.43%	62
2026 Q1	$427K	Buy	8,318 +174	+2%	+$8.12K	0.35%	66
2025 Q4	$436K	Buy	+8,144	New	+$221K	0.35%	67

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Sankala Group's MRNA Position: Q2 2026 in Review

Sankala Group increased its Moderna (MRNA) stake by 21% in Q2 2026, buying an estimated $92.5K and bringing the position to 10,105 shares worth $644K. The position accounts for 0.43% of the portfolio, ranked #62.

Sankala Group first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Sankala Group held 10,105 shares of Moderna worth $644K as of Q2 2026.
Sankala Group bought 1,787 Moderna shares in Q2 2026, an estimated $92.5K.
Moderna made up 0.43% of Sankala Group's portfolio in Q2 2026, its #62 holding.
Sankala Group first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.